ArticlePathogens (Basel, Switzerland)2021
Genomic and Phenotypic Analysis of Multidrug-Resistant
Article in Pathogens (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 1 synthesis or guideline pooled it, 47 citations in OpenAlex.
- CRISPR-Cas systems as next-generation antimicrobials: a systemic review of mechanisms, delivery strategies, and translational challenges.Frontiers in microbiology · 2026Pooled it
- Multiplex RPA-CRISPR/Cas12a Assay for Rapid Detection of Class D OXA-Type Carbapenem-ResistantBiosensors · 2026Article
- Genomic landscape of 340 virulent Acinetobacter bacteriophages reveals anti-CRISPR-enriched candidates for therapeutic prioritization.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- Colistin Resistance: From Laboratory Research to Modern Clinical Management.Antibiotics (Basel, Switzerland) · 2026Review
- Genomic insights into the genetic diversity, resistance determinants, and plasmid content of carbapenem-resistant Acinetobacter baumannii clinical isolates.Archives of microbiology · 2026Article
- CRISPR-Cas opens a new era of antimicrobial therapy as a powerful gene editing tool.World journal of microbiology & biotechnology · 2025Review
- Article
- Whole-genome sequencing ofMicrobial genomics · 2025Article
- The Evolution of Antimicrobial Resistance inAntibiotics (Basel, Switzerland) · 2025Review
- The intricacies ofFrontiers in microbiology · 2025Review
- Two multidrug-resistantHeliyon · 2024Article
- Current Knowledge on CRISPR Strategies Against Antimicrobial-Resistant Bacteria.Antibiotics (Basel, Switzerland) · 2024Review
- Interrelation Between Pathoadaptability Factors and Crispr-Element Patterns in the Genomes ofPathogens (Basel, Switzerland) · 2024Article
- H-NS is a Transcriptional Repressor of the CRISPR-Cas System in Acinetobacter baumannii ATCC 19606.Journal of microbiology (Seoul, Korea) · 2024Article
- Role of CRISPR-Cas systems and anti-CRISPR proteins in bacterial antibiotic resistance.Heliyon · 2024Review
- Article
- International Clones of High Risk of Acinetobacter Baumannii-Definitions, History, Properties and Perspectives.Microorganisms · 2023Review
- CRISPR-Based Gene Editing inPharmaceuticals (Basel, Switzerland) · 2023Review
- Analysis of CRISPR/Cas Genetic Structure, Spacer Content and Molecular Epidemiology in BrazilianPathogens (Basel, Switzerland) · 2023Article
- Molecular characterization and comparative genomic analysis ofMicrobial genomics · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.